Related Experiment Video
Updated: May 12, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Biologic therapy in rheumatoid arthritis.
1Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain. jcanete@clinic.ub.es
Current Topics in Medicinal Chemistry
|April 12, 2013
Summary
Biologic therapies offer effective rheumatoid arthritis (RA) treatment, with manageable safety profiles. Combining biologics shows no added benefit but increases infection risk, necessitating further research for optimized RA therapy.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Biologic therapies have significantly advanced rheumatoid arthritis (RA) treatment.
- Disease remission is now an achievable goal for RA patients.
- Over a decade of use has clarified the safety profile of biologics, manageable with careful patient selection and monitoring.
Purpose of the Study:
- To review the efficacy and safety of biologic therapies in RA treatment.
- To compare the effectiveness of different classes of biologic agents.
- To evaluate the outcomes of combining biologic therapies in RA management.
Main Methods:
- Review of clinical data and published literature on biologic therapies for RA.
- Analysis of safety profiles and efficacy data for various biologic agents (anti-TNF, anti-IL-6, anti-B cell, anti-T cell).
- Examination of studies investigating combination biologic therapy in RA.
Main Results:
- All biologic agents, despite varying mechanisms of action, demonstrate comparable efficacy in RA treatment.
- Combination therapy with two biologics did not yield additive clinical benefits.
- An increased risk of infection was observed with combination biologic therapy.
Conclusions:
- Biologic therapies are effective for RA, with well-defined safety considerations.
- Current evidence does not support combining biologic agents due to lack of added efficacy and increased infection risk.
- Further research is essential to refine the use of existing and novel targeted therapies for optimal RA management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...